Evaluating SCTB35 for treating systemic lupus erythematosus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter Phase Ib/II clinical trial aims to assess the safety, tolerability, and efficacy of SCTB35 in patients diagnosed with systemic lupus erythematosus (SLE). The study includes dose-escalation and dose-expansion phases, where the escalation cohorts will help determine the maximum tolerated dose and the recommended phase II dose (RP2D). A Safety Review Committee will evaluate safety data and recommend appropriate dose levels for the expansion cohorts, which will further compare the efficacy and safety of SCTB35.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years；
2. Diagnosed with SLE for ≥12 weeks prior to screening (2019-ACR/EULAR criteria);
3. SLEDAI-2K ≥ 8 at screening, or ≥6 if there is hypocomplementemia or elevated anti-dsDNA antibody levels;
4. Positive for ANA (1:80) or positive for anti-dsDNA and/or anti-Sm antibodies within the last 12 months or at screening;
5. Currently receiving ≥1 stable dose of standard treatment: oral corticosteroids, antimalarials, or conventional immunosuppressive drugs

   1. Stable corticosteroid dose for ≥4 weeks prior to baseline;
   2. Stable dose of antimalarial drugs for ≥4 weeks prior to baseline;
   3. Stable dose of immunosuppressive agents for ≥4 weeks prior to baseline;
6. All male participants or females of reproductive potential must agree to use reliable contraception with their partner from signing the ICF through 6 months after the last dose of the study drug;
7. Understanding of the study procedures and voluntary signing of the informed consent form.

Exclusion Criteria:

1. Severe active or unstable lupus-related neuropsychiatric disorders;
2. Other autoimmune diseases that may interfere with efficacy evaluation;
3. Catastrophic antiphospholipid syndrome;
4. Received treatments that may affect the drug's effect:
5. Received live vaccines or attenuated vaccines within 28 days prior to baseline or screening;
6. Clinically significant bleeding risk;
7. Abnormal laboratory results:

   1. AST or ALT \>2.5 x ULN;
   2. Total bilirubin \>1.5 x ULN;
   3. ANC \<1.5x10⁹/L;
   4. Platelets \<75x10⁹/L;
   5. Hemoglobin \<100g/L;
8. eGFR \<30 mL/min/1.73 m²;
9. Positive serum HCG;
10. Received any investigational treatment within 30 days prior to baseline or within 5 half-lives of the investigational drug (whichever is longer);
11. Participants with recurrent, chronic, or other active infections as assessed by the investigator;
12. Severe or uncontrolled disease, which would prevent participation in the study;
13. Positive viral serology tests, including HIV, HCV, and HBV;
14. Tuberculosis screening: Known active tuberculosis or latent tuberculosis infection (LTBI);
15. Any type of active infection except nail bed fungal infections;
16. Severe infections;
17. History of progressive multifocal leukoencephalopathy (PML);
18. Diagnosed with type 1 or type 2 diabetes with poor control;
19. Uncontrolled hypertension (systolic \>140 mmHg or diastolic \>90 mmHg);
20. History of malignancy within 5 years prior to baseline;
21. Alcohol abuse or drug misuse within 12 months prior to screening;
22. Intolerance to the study drug or contraindications, including a history of severe allergic reactions to monoclonal antibodies or any component of SCTB35 injection;
23. Required hospitalization for major surgery within 4 weeks prior to screening or within 12 weeks post-study drug administration;
24. Participants with mental disorders or poor compliance;
25. Severe lupus nephritis;
26. History of solid organ or hematopoietic stem cell/bone marrow transplant, or expected to undergo transplant surgery during the study;
27. Pregnant or breastfeeding;
28. Any other condition that the investigator deems unsuitable for participation in the study.

Where it's running

• Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
  Beijing, China Recruiting
• Xuanwu Hospital, Capital Medical University
  Beijing, China Not yet recruiting
• Jilin Provincial People's Hospital
  Changchun, China Not yet recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, China Not yet recruiting
• Zhejiang Provincial People's Hospital
  Hangzhou, China Not yet recruiting
• The First People's Hospital of Jiujiang City
  Jiujiang, China Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases

  This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.

  Recruiting Early Phase 1 Peking University Third Hospital · Beijing · NCT07301164

• SCTB41 plus chemotherapy vs tislelizumab plus chemotherapy as first-line treatment for advanced NSCLC

  This trial tests SCTB41 plus chemotherapy to see if it helps people with advanced NSCLC more than tislelizumab plus chemotherapy.

  Recruiting Phase 2/3 Sinocelltech Ltd. · Guangzhou, Guangdong · NCT07662395

• SCTB35 with Gemcitabine and Oxaliplatin in relapsed or refractory DLBCL

  This trial tests whether SCTB35 added to gemcitabine and oxaliplatin helps people with relapsed or refractory diffuse large B-cell lymphoma stay disease-free longer compared with rituximab plus gemcitabine and oxaliplatin.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing · NCT07570823

• SCTB35 plus Lenalidomide for relapsed or refractory follicular lymphoma

  This trial tests whether SCTB35 given with Lenalidomide can help people whose follicular lymphoma has come back or stopped responding to prior treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07562022

• SCT800 for preventing and treating bleeds in previously untreated severe hemophilia A patients

  This test tries SCT800, a recombinant factor VIII, as regular prevention and to treat bleeds in male patients with severe hemophilia A who haven't had prior factor VIII treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07437404

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.